Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...

A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

Sarfaraz K. Niazi, PhD, dives into the role that biosimilar associations and organizations play in promoting biosimilars as ...

When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...

Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access ...

Number 4: Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the ...

The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...

The Top 5 Biosimilar Articles for the Week of December 2 ...